Promising Antidiabetic Drugs, Medicinal Plants and Herbs: An Update

作者:Yatoo Mohd Iqbal*; Saxena Archana; Gopalakrishnan Arumugam; Alagawany Mahmoud; Dhama Kuldeep
来源:International Journal of Pharmacology, 2017, 13(7): 732-745.
DOI:10.3923/ijp.2017.732.745

摘要

Diabetes is a chronic endocrine disease with global prevalence and rising incidence. Diabetes represents a major health issue in all age groups in the present times owing to its multisystem involvement and serious complications. Despite drug development and therapeutic interventions, successful treatment of diabetes still remains a challenge and worldwide research is focused on these aspects. Conventional antidiabetic medicines include injectable insulins, sulfonylureas, biguanides, glucosidase inhibitors and glinides. New class include inhalable insulins, incretin mimetics, amylin analogues, gastric inhibitory polypeptide analogues, peroxisome proliferator activated receptors and dipeptidyl peptidase-4 inhibitors. From effectiveness of synthetic drugs, chemicals or hormones to issues of cost,availability and side effects, novelty in preparations to methods of administration, all fields are explored for better management of the disease. Medicinal plants with antidiabetic potential have been recent areas of research. Asteraceae, Araliaceae, Cucurbitaceae, Lamiaceae, Leguminoseae, Liliaceae, Moraceae and Rosaceae are the major antidiabetic plant families. The most active plants are Allium sativum, Gymnema sylvestre, Citrullus colocynthis, Trigonella foenum greacum, Momordica charantia and Ficus bengalensis. Their phytoconstituents have shown promising results in diabetes management; but need to be properly evaluated at molecular, physiological, pharmacological and toxicological levels for various prophylactic and therapeutic attributes, mechanisms of action, efficacy and safety before application in diabetes. The common phytoconstituents include polyphenols, flavonoids, terpenoids, tannins, alkaloids, saponins etc. Exploration of novel targets like glucagon-like peptide-1 (GLP-1), sodium-glucose co-transporter 2 (SGLT-2) and dipeptidyl peptidase 4 (DPP-4) for antidiabetic drugs and medicinal plants with emphasis on site specific effectiveness and overcoming problems of resistance, side effects, prolonged usage and high cost, are being investigated for future research.